BridgeBio CEO’s trusts sell 80,000 shares

BridgeBio Pharma CEO Neil Kumar reported insider sales executed by family trusts holding company stock.

Rhea-AI Filing Summary

BridgeBio Pharma CEO Neil Kumar reported insider sales executed by family trusts holding company stock. On March 12–13, 2026, trusts for which he is co‑trustee sold a total of 80,000 shares of BridgeBio common stock in open‑market transactions at prices around the high‑$60s to about $70.18 per share.

After these sales, one family irrevocable trust held 635,686 shares, a revocable trust held 4,438,447 shares, and Kumar also reported 234,451 shares held directly. The transactions were carried out under a pre‑arranged Rule 10b5‑1 sales plan, and Kumar disclaimed beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 80,000 shares

Net Sell 11 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 80,000 shs ($5.50M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,690	$68.3634	$662K
Sale	Common Stock	10,310	$69.1997	$713K
Sale	Common Stock	10,241	$68.3864	$700K
Sale	Common Stock	9,759	$69.2251	$676K
Sale	Common Stock	14,337	$68.4808	$982K
Sale	Common Stock	5,363	$69.3176	$372K
Sale	Common Stock	300	$70.15	$21K
Sale	Common Stock	13,885	$68.4686	$951K
Sale	Common Stock	5,815	$69.2913	$403K
Sale	Common Stock	300	$70.15	$21K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 635,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 4,438,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 234,451 shares (Direct)

Footnotes (11)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
2. F2. Represents the weighted average sale price of the shares sold from $67.935 to $68.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
4. F4. Represents the weighted average sale price of the shares sold from $68.94 to $69.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. F5. Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. F6. Represents the weighted average sale price of the shares sold from $67.935 to $68.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
7. F7. Represents the weighted average sale price of the shares sold from $68.94 to $69.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
8. F8. Represents the weighted average sale price of the shares sold from $67.76 to $68.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
9. F9. Represents the weighted average sale price of the shares sold from $68.76 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
10. F10. Represents the weighted average sale price of the shares sold from $67.82 to $68.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
11. F11. Represents the weighted average sale price of the shares sold from $68.82 to $69.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

FAQ

What insider activity did BridgeBio (BBIO) report for CEO Neil Kumar?

BridgeBio reported that CEO Neil Kumar’s associated trusts sold 80,000 shares of common stock. These open‑market sales on March 12–13, 2026 were executed under a pre‑arranged Rule 10b5‑1 trading plan and involved only indirect trust holdings.

At what prices were the BridgeBio (BBIO) shares sold in this Form 4?

The 80,000 BridgeBio shares were sold at weighted average prices in the high-$60s to about $70.18 per share. Footnotes state detailed price ranges, and Kumar will provide exact trade breakdowns upon request to regulators, the company, or shareholders.

How many BridgeBio (BBIO) shares do the Kumar-related trusts hold after the sales?

After the reported transactions, a family irrevocable trust held 635,686 shares and a revocable trust held 4,438,447 shares. Both entities list Neil Kumar as co‑trustee, and these positions reflect substantial ongoing indirect ownership in BridgeBio stock.

Does Neil Kumar still own BridgeBio (BBIO) shares directly after this Form 4?

Yes. The filing shows Neil Kumar holding 234,451 BridgeBio shares directly after the reported period. This direct position is separate from the much larger indirect holdings reported for the family irrevocable and revocable trusts where he serves as co‑trustee.

Were the BridgeBio (BBIO) insider sales part of a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were executed under a Rule 10b5‑1 sales plan adopted on March 31, 2025. Such plans are pre‑scheduled arrangements intended to allow insiders to sell shares over time in a systematic manner.

Does Neil Kumar claim full beneficial ownership of the BridgeBio (BBIO) trust shares?

No. The filing states Kumar disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest. This legal language clarifies how ownership is treated for securities law purposes, despite his role as co‑trustee of the trusts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 06:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S(1)		14,337	D	$68.4808(2)	661,349	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/12/2026		S(1)		5,363	D	$69.3176(4)	655,986	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/12/2026		S(1)		300	D	$70.15(5)	655,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/12/2026		S(1)		13,885	D	$68.4686(6)	4,464,562	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/12/2026		S(1)		5,815	D	$69.2913(7)	4,458,747	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/12/2026		S(1)		300	D	$70.15(5)	4,458,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/13/2026		S(1)		9,690	D	$68.3634(8)	645,996	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/13/2026		S(1)		10,310	D	$69.1997(9)	635,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/13/2026		S(1)		10,241	D	$68.3864(10)	4,448,206	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	03/13/2026		S(1)		9,759	D	$69.2251(11)	4,438,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								234,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $67.935 to $68.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $68.94 to $69.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $67.935 to $68.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $68.94 to $69.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $67.76 to $68.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

9. Represents the weighted average sale price of the shares sold from $68.76 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

10. Represents the weighted average sale price of the shares sold from $67.82 to $68.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

11. Represents the weighted average sale price of the shares sold from $68.82 to $69.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.